Welcome to Viz.ai . At Viz.ai, we harness the power of artificial intelligence (AI) to improve patient outcomes. Our comprehensive AI-powered care coordination solution leverages advanced, FDA-cleared algorithms to analyze medical imaging data, including CT scans, EKGs, echocardiograms and more, providing real-time insights and automated assessments to accelerate diagnosis …

Viz Neuro. AI-powered suite of solutions tailored to accelerate the detection and treatment of suspected neuro diseases. Learn more; Viz Cardio. AI-powered suite of solutions developed to meet cardiovascular needs.

Frustrated by the unnecessary delays that had cost his patient her life, neurosurgeon Dr. Chris Mansi committed to finding a better way. Dr. Mansi joined forces with machine learning post-doc Dr. David Golan and together they founded Viz.ai, in 2016, with a goal of using artificial intelligence to make healthcare work faster and smarter.

2023年11月22日 · San Francisco-based Viz.ai is at the forefront of medical companies using artificial intelligence to improve care for patients. An alumnus of the 2021 Forbes Next Billion-Dollar Startups list, it ...

Viz.ai | 38,378 followers on LinkedIn. AI-powered disease detection and care coordination platform | Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of ...

2022年1月3日 · The company, which made the cut for Forbes Next Billion-Dollar Startups list in 2021, has raised $150 million from investors that include Insight Partners, Kleiner Perkins and Scale Venture ...

2025年1月14日 · Ana Cortes, right, was treated for a stroke at Orlando Health Bayfront Hospital. Doctors used VizAI, a artificial intelligence program to send scans of her brain to an on-call specialist.

2024年3月26日 · SAN FRANCISCO — Viz.ai, Inc., the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic collaboration with Medtronic to improve the coordination of cryptogenic stroke patient care …

2023年8月16日 · SAN FRANCISCO — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received a De Novo approval by the U.S. Food and Drug Administration (FDA) for its Viz HCM module, a hypertrophic cardiomyopathy (HCM) artificial intelligence (AI) detection algorithm, creating a new regulatory category for …

December 3, 2024—Viz.ai announced new clinical data showing positive outcomes with real-world impact of the company’s technology in clinical practice for treatment of patients with cerebral aneurysms or abdominal aortic aneurysms (AAAs).

2021年3月17日 · Today Viz.ai, an artificial intelligence care coordination company, shared the closing of its Series C funding round worth $71 million. Scale Venture Partners and Insight Partners led the financing with participation from Greenoaks, Kleiner Perkins, Threshold Ventures, CRV, Innovation Endeavors and Susa Ventures.

Viz.ai makes imaging viewable right on my phone and allows me to not only confirm the occlusion, but simultaneously evaluate the rest of anatomy and scout any potential complications including carotid stenosis, vessel tortuously, and aortic arch type.

2024年1月8日 · Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 230 million lives across 1,500+ hospitals and health systems in the U.S. and Europe.

2018年2月14日 · The US Food and Drug Administration (FDA) has granted permission to market VizAI’s clinical decision support software, called Contact application, for the identification and notification of a potential stroke.

2022年4月7日 · Artificial intelligence-backed health-tech startup Viz.ai announced a $100 million Series D funding round that brings its total valuation to $1.2 billion.

2023年3月21日 · The FDA nod makes Viz’s AI tool the first to be given the green light to detect and triage suspected cases of AAA, according to the Fierce 15 honoree.

Viz.ai, cofounded by Dr. Chris Mansi, is transforming stroke treatment through its AI-driven system, enhancing the speed and accuracy of diagnosing and treating strokes, particularly large vessel occlusions (LVOs).

February 8, 2023—Viz.ai and TeleSpecialists LLC announced that new data from the VALIDATE study were presented at ISC 2023, the International Stroke Conference, held February 8-10 in Dallas, Texas.

2022年11月16日 · SAN FRANCISCO, N.Y. — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic partnership with Vastrax, the leading full-service, vascular clinical research organization (CRO).Together, Viz.ai and Vastrax will accelerate clinical trial enrollment for research on novel neurovascular therapies.

Bryan Hartley talks with Neurosurgeon Dr. Chris Mansi about the origin story of Viz.ai, a company using Artificial Intelligence to Shorten Time to Treatment and Improve Access to Care for Stroke Patients.